Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Monkhorst

Showing results (11-20 of 103) with videos related to

Pageof 11
Sort By:
The Journal of Molecular Diagnostics : JMD|January 25, 2021
Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring HospitalsMichiel van de Ven, Hendrik Koffijberg, Valesca Retèl, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 1, 2018
Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug ConjugatesLaurel M Schunselaar, Kim Monkhorst, Vincent van der Noort, et al.
Acta Chirurgica Belgica|February 26, 2024
Survival difference between patients with single versus multiple metastatic lymph nodes and the role of histology in pathological stage II-N1 non-small cell lung cancerJulianne Ruiter, Adrianus de Langen, Kim Monkhorst, et al.
Cancer Cell|October 12, 2016
SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of OriginGiustina Ferone, Ji-Ying Song, Kate D Sutherland, et al.
Cell|December 1, 2009
RNF12 is an X-Encoded dose-dependent activator of X chromosome inactivationIris Jonkers, Tahsin Stefan Barakat, Eskeatnaf Mulugeta Achame, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2018
Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLCBianca van Veggel, Adrianus J de Langen, Sayed M S Hashemi, et al.
The Lancet. Respiratory Medicine|January 21, 2019
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trialMaria J Disselhorst, Josine Quispel-Janssen, Ferry Lalezari, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responsesBianca van Veggel, Adrianus J de Langen, Sayed Hashemi, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
Divergence of DNA tumor mutations in cerebrospinal fluid in metastatic breast cancer patients with leptomeningeal metastasesPeter H Wessels, Sten Cornellisen, Kim Monkhorst, et al.
British Journal of Cancer|August 1, 2018
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatmentAdrianus J de Langen, M Jebbink, Sayed M S Hashemi, et al.
Pageof 11

Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
The Journal of Molecular Diagnostics : JMD|January 25, 2021
Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring HospitalsMichiel van de Ven, Hendrik Koffijberg, Valesca Retèl, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 1, 2018
Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug ConjugatesLaurel M Schunselaar, Kim Monkhorst, Vincent van der Noort, et al.
Acta Chirurgica Belgica|February 26, 2024
Survival difference between patients with single versus multiple metastatic lymph nodes and the role of histology in pathological stage II-N1 non-small cell lung cancerJulianne Ruiter, Adrianus de Langen, Kim Monkhorst, et al.
Cancer Cell|October 12, 2016
SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of OriginGiustina Ferone, Ji-Ying Song, Kate D Sutherland, et al.
Cell|December 1, 2009
RNF12 is an X-Encoded dose-dependent activator of X chromosome inactivationIris Jonkers, Tahsin Stefan Barakat, Eskeatnaf Mulugeta Achame, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2018
Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLCBianca van Veggel, Adrianus J de Langen, Sayed M S Hashemi, et al.
The Lancet. Respiratory Medicine|January 21, 2019
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trialMaria J Disselhorst, Josine Quispel-Janssen, Ferry Lalezari, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responsesBianca van Veggel, Adrianus J de Langen, Sayed Hashemi, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
Divergence of DNA tumor mutations in cerebrospinal fluid in metastatic breast cancer patients with leptomeningeal metastasesPeter H Wessels, Sten Cornellisen, Kim Monkhorst, et al.
British Journal of Cancer|August 1, 2018
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatmentAdrianus J de Langen, M Jebbink, Sayed M S Hashemi, et al.
Pageof 11